AtriCure, Inc. (ATRC)
| Market Cap | 1.44B -3.0% |
| Revenue (ttm) | 552.16M +15.0% |
| Net Income | -4.59M |
| EPS | -0.10 |
| Shares Out | 50.64M |
| PE Ratio | n/a |
| Forward PE | 255.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 732,783 |
| Open | 28.12 |
| Previous Close | 28.12 |
| Day's Range | 28.03 - 29.45 |
| 52-Week Range | 25.52 - 43.18 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | 47.00 (+65.03%) |
| Earnings Date | May 5, 2026 |
About ATRC
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation Sys... [Read more]
Financial Performance
In 2025, AtriCure's revenue was $534.53 million, an increase of 14.88% compared to the previous year's $465.31 million. Losses were -$11.45 million, -74.39% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ATRC stock is "Buy." The 12-month stock price target is $47.0, which is an increase of 65.03% from the latest price.
News
AtriCure Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and amendments to stock plans. All proposals, including executive compensation, were approved with over 91% of shares voted. No questions were raised during the session.
AtriCure Transcript: Bank of America Global Healthcare Conference 2026
Guidance for 2026 targets 12%-14% revenue growth, driven by innovation and new product launches, with profitability and positive cash flow expected to improve further. Major clinical trials and guideline changes are set to expand the addressable market, while competitive differentiation is reinforced by exclusive data and next-generation products.
AtriCure price target raised to $55 from $53 at Canaccord
Canaccord raised the firm’s price target on AtriCure (ATRC) to $55 from $53 and keeps a Buy rating on the shares. The firm said they delivered a modest Q1 revenue…
AtriCure participates in a conference call with JPMorgan
Medical Supplies & Devices Analyst Lozada, along with CFO Wirick, participate in a post-1Q earnings conference call on May 6 at 2 pm hosted by JPMorgan. Webcast Link Published first…
AtriCure Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 14% year-over-year to $141.2 million, with strong gains in pain management, open ablation, and appendage management. Adjusted EBITDA nearly doubled, and BoxX-NoAF trial enrollment is ahead of schedule, supporting a positive outlook for 2026.
AtriCure Earnings release: Q1 2026
AtriCure released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
AtriCure Quarterly report: Q1 2026
AtriCure has published its Q1 2026 quarterly earnings report on May 5, 2026.
AtriCure Slides: Q1 2026
AtriCure has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
AtriCure reports Q1 EPS ,0c consensus (6c)
Reports Q1 revenue $141.2M, consensus $139.8M. “Our first quarter results reflect the durability of AtriCure’s (ATRC) growth model, fueled by disciplined execution and increased adoption of our innova...
AtriCure Reports First Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure to Announce First Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure Proxy statement: Proxy filing
AtriCure filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
AtriCure Proxy statement: Proxy filing
AtriCure filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
AtriCure initiated with a Buy at Freedom Capital
Freedom Capital initiated coverage of AtriCure (ATRC) with a Buy rating and $43 price target The firm’s bullish outlook is driven by the assumption that the Afib franchise can continue…
AtriCure Transcript: The Citizens Life Sciences Conference 2026
Guidance for 2026 projects 12%-14% organic growth, led by pain management and open heart surgery innovations. New product launches, especially in pain management and appendage management, are driving adoption and ASP uplift, while clinical trials like LeAAPS and BoxX-NoAF are set to expand future opportunities.
3 Small-Cap ‘Strong Buy’ Stocks with Big Upside in 2026, According to Analysts
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Diversified Energy Company ($DEC), Atricure ($ATRC), and Innoviva ($INVA) as companies wi...
AtriCure to Participate in the Citizens Life Sciences Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure price target lowered to $55 from $60 at UBS
UBS lowered the firm’s price target on AtriCure (ATRC) to $55 from $60 and keeps a Buy rating on the shares. AtriCure posted another quarter of sales and EPS outperformance…
AtriCure price target lowered to $53 from $64 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on AtriCure (ATRC) to $53 from $64 and keeps a Buy rating on the shares. The firm said they reported Q4…
Oppenheimer downgrades AtriCure on new competition from Edwards
Oppenheimer downgraded AtriCure (ATRC) to Perform from Outperform without a price target following the Q4 report. Last week, Edwards Lifesciences (EW) announced it was pursuing new left atrial appenda...
AtriCure downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded AtriCure (ATRC) to Perform from Outperform and removed the firm’s prior $44 price target
AtriCure price target lowered to $52 from $60 at Citizens
Citizens analyst Daniel Stauder lowered the firm’s price target on AtriCure (ATRC) to $52 from $60 and keeps an Outperform rating on the shares. The company continues to make progress…
AtriCure Earnings Call Transcript: Q4 2025
2025 saw 15% revenue growth, margin expansion, and strong cash generation, led by pain management and open ablation. 2026 guidance projects 12–14% growth, with continued innovation, positive cash flow, and margin improvement, despite competitive and reimbursement headwinds.
AtriCure Annual report: Q4 2025
AtriCure has published its Q4 2025 annual report on February 17, 2026.